Foscarnet for suppression of human immunodeficiency virus replication. - Wikidata - wikimedia - TriplyDB

Foscarnet for suppression of human immunodeficiency virus replication.

Foscarnet for suppression of human immunodeficiency virus replication.

http://www.wikidata.org/entity/Q33751608

about

Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.Foscarnet alters antidiuretic hormone-mediated transport.Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS Synthesis and antiviral evaluation of SATE-foscarnet prodrugs and new foscarnet-AZT conjugates.Pharmacologic considerations for antiviral drug development.In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine.Cytomegalovirus retinitis in persons with AIDS.

P2860

Q28365182-1E0495ED-ED11-4B75-B0C3-75594E657335 Q28367722-FCA90A35-075F-49C7-82BC-36021CAE0C4A Q28369167-A03540E7-E133-4F6B-AF1C-A4097B1D510C Q28378983-F3305802-1345-4C74-AB84-0E81A8786647 Q35118174-DCA78A7E-BE64-4691-B4DC-EA24147D593F Q35118306-5F7639F3-4889-48D6-894A-B70D56026EBD Q35129803-39D6A8B0-6224-4D53-A44B-8781356A85E0 Q40983982-8DDE6045-ADE1-42CB-BEE3-4CB483B7C8A4 Q41172065-C54A17EF-7C2A-4760-BE12-FD437338E24A Q41748484-161D677E-BCD1-4787-A24D-20AEAC755DB1 Q50008558-B8FEFEF6-79EF-4955-AC4A-5E010F905998

P2860

Foscarnet for suppression of human immunodeficiency virus replication.

http://www.wikidata.org/entity/Q33751608

description

1994 nî lūn-bûn

@nan

1994 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1994 թվականի մարտին հրատարակված գիտական հոդված

@hy

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

name

Foscarnet for suppression of human immunodeficiency virus replication.

@ast

Foscarnet for suppression of human immunodeficiency virus replication.

@en

type

label

Foscarnet for suppression of human immunodeficiency virus replication.

@ast

Foscarnet for suppression of human immunodeficiency virus replication.

@en

prefLabel

Foscarnet for suppression of human immunodeficiency virus replication.

@ast

Foscarnet for suppression of human immunodeficiency virus replication.

@en

P1433

Q33751608-4315BBC2-E414-47A6-A7ED-FA3A0059F0FB

P1476

Q33751608-AD54F761-0703-48D7-B79D-2AFB061BBFC3

P2093

Q33751608-413CD06E-8622-46FE-8D0B-4236F7CE4698

Q33751608-4570220B-69FC-493A-BB6E-6073503502FF

Q33751608-8616592A-E407-4128-98C2-5C93B0427ABE

Q33751608-88B83AFA-35AD-4598-9F21-5BBEE7D0D1D6

Q33751608-B9AF47A1-73D6-4618-8742-4435F462C74F

Q33751608-BBD47DBB-3456-4E8F-8941-FA93BDA448A1

Q33751608-C798F2B5-2906-408C-86DB-676CDE228FA6

Q33751608-CAEDA5EE-11F7-46A8-A69E-B79AF048585D

P2860

Q33751608-53FD81E0-A96E-4316-A2D7-7DB1A71ED432

Q33751608-59C5729F-E373-49C4-A604-B9BE73677123

Q33751608-85DFB240-135F-4601-805D-61F736123A12

Q33751608-8734AC3F-4854-43C3-BC7F-C140C56D8943

Q33751608-ABA3B546-9633-451D-B169-34DC9020181D

Q33751608-B2B546CE-6E97-4CF8-95E4-70246A457DE7

Q33751608-CA80C71F-1727-4AA2-BDD2-AAA136D7D7C2

Q33751608-D85FCA4B-7E7A-4A11-BDEE-C3976EF74980

Q33751608-DA266005-8C34-4846-BD3F-5C201B84B0D6

Q33751608-DA37C279-26D9-4DEE-BC3F-BA89A2928776

P304

Q33751608-A4E8B908-3018-4E37-A484-39A926813668

P31

Q33751608-98F7D128-C77E-47B9-B010-61EB6119DB4B

P356

Q33751608-1D6B4C4D-9F4C-4953-A060-00DCE6EE0F2B

P407

Q33751608-944467C4-D61A-4214-B542-5FEF68CCD28C

P433

Q33751608-DF5F9E38-2CC4-4EC9-BD43-1DBB04CF3626

P478

Q33751608-86B204C8-18B6-4F28-9E1D-0AB66930CC65

P577

Q33751608-A0C72F7A-0177-46CD-AD6B-A4E4EDAA8BC7

P698

Q33751608-E7A95461-F208-490D-A26C-53B6D63B8A29

P932

Q33751608-433EC1EC-6095-4AFB-873F-D4BEE66FC588

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Foscarnet for suppression of human immunodeficiency virus replication.

@en

P2093

A C Collier

http://www.w3.org/2001/XMLSchema#string

C C Beatty

http://www.w3.org/2001/XMLSchema#string

C E Jones

http://www.w3.org/2001/XMLSchema#string

C V Fletcher

http://www.w3.org/2001/XMLSchema#string

D Bennett

http://www.w3.org/2001/XMLSchema#string

F S Rhame

http://www.w3.org/2001/XMLSchema#string

H H Balfour

http://www.w3.org/2001/XMLSchema#string

M F Para

http://www.w3.org/2001/XMLSchema#string

P2860

Forecasting individual pharmacokinetics

Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate

Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.

Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053)

Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.

Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.

Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.

Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.

P304

604-607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.38.3.604

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

1994-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7911290

http://www.w3.org/2001/XMLSchema#string

P932

284505

http://www.w3.org/2001/XMLSchema#string